Sah Ashok Kumar, Afzal Mohd, Elshaikh Rabab H, Abbas Anass M, Shalabi Manar G, Prabhakar Pranav Kumar, Babker Asaad M A, Khalimova Fariza Tursunbaevna, Sabrievna Velilyaeva Aliya, Choudhary Ranjay Kumar
Department of Medical Laboratory Sciences, College of Applied and Health Sciences, A' Sharqiyah University, Ibra 400, Oman.
Department of Medical Laboratory Technology, Arogyam Institute of Paramedical & Allied Sciences (Affiliated to H.N.B. Uttarakhand Medical Education University), Roorkee 247661, India.
Life (Basel). 2025 May 13;15(5):779. doi: 10.3390/life15050779.
Liver cirrhosis continues to be a major global health issue, contributing to high morbidity and mortality due to its progressive nature and associated complications. This review explores recent advancements in the diagnosis and treatment of liver cirrhosis and its related syndromes. Non-invasive diagnostic tools, such as elastography and serum biomarkers, have significantly improved early detection, reducing the need for liver biopsies. Advanced imaging techniques, including MRI and CT, further enhance diagnostic accuracy. In parallel, molecular and genomic research is providing new insights into the pathogenesis of the disease, paving the way for precision medicine. On the treatment front, pharmacological innovations, such as antifibrotic agents and targeted therapies, show promise in slowing disease progression. Endoscopic interventions like variceal banding are improving the management of complications, while advancements in liver transplantation and artificial liver support systems offer life-saving alternatives. Regenerative medicine, particularly stem cell therapy and tissue engineering, is emerging as a promising strategy for liver repair. Managing cirrhosis-related syndromes, including portal hypertension, ascites, hepatic encephalopathy, and hepatorenal syndrome, now involves evolving therapeutic approaches such as transjugular intrahepatic portosystemic shunt (TIPS) and novel pharmacotherapies. Prognostic scoring systems like the MELD and Child-Pugh are being refined with new biomarkers for better risk stratification. The future of cirrhosis care will likely involve the integration of artificial intelligence and machine learning for early diagnosis and personalized treatments, alongside emerging therapies currently under investigation. Despite these advancements, challenges such as costs, accessibility, and healthcare disparities remain barriers to widespread adoption. This review highlights the importance of incorporating innovative diagnostic and therapeutic strategies into clinical practice to improve the outcomes for patients with liver cirrhosis and its complications.
肝硬化仍然是一个重大的全球健康问题,因其渐进性本质和相关并发症导致高发病率和死亡率。本综述探讨了肝硬化及其相关综合征诊断和治疗方面的最新进展。非侵入性诊断工具,如弹性成像和血清生物标志物,显著改善了早期检测,减少了肝活检的需求。先进的成像技术,包括磁共振成像(MRI)和计算机断层扫描(CT),进一步提高了诊断准确性。与此同时,分子和基因组研究为该疾病的发病机制提供了新的见解,为精准医学铺平了道路。在治疗方面,抗纤维化药物和靶向治疗等药理学创新在减缓疾病进展方面显示出前景。诸如静脉曲张套扎术等内镜干预措施正在改善并发症的管理,而肝移植和人工肝支持系统的进展提供了挽救生命的替代方案。再生医学,特别是干细胞疗法和组织工程,正成为一种有前景的肝脏修复策略。管理与肝硬化相关的综合征,包括门静脉高压、腹水、肝性脑病和肝肾综合征,现在涉及不断发展的治疗方法,如经颈静脉肝内门体分流术(TIPS)和新型药物疗法。诸如终末期肝病模型(MELD)和Child-Pugh评分系统等预后评分系统正在通过新的生物标志物进行完善,以实现更好的风险分层。肝硬化护理的未来可能会涉及将人工智能和机器学习整合到早期诊断和个性化治疗中,以及目前正在研究的新兴疗法。尽管有这些进展,但成本、可及性和医疗保健差距等挑战仍然是广泛采用的障碍。本综述强调了将创新的诊断和治疗策略纳入临床实践以改善肝硬化及其并发症患者预后的重要性。